SynthesisInternational journal of chronic obstructive pulmonary disease2025
A Systematic Review and Meta-Analysis on the Safety and Efficacy of Rosuvastatin as an Adjunctive Therapy in Acute Exacerbations of Chronic Obstructive Pulmonary Disease.
Synthesis in International journal of chronic obstructive pulmonary disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Purpose: Acute exacerbations of chronic obstructive pulmonary disease (COPD) severely impact patient health, and current treatments often fail to adequately control inflammation and lung function decline. Statins have shown potential in managing AECOPD. This study conducts a systematic review and meta-analysis to evaluate the effects of rosuvastatin, aiming to provide precise treatment recommendations. Research methods: Using "Pulmonary Disease, Chronic Obstructive" and "Rosuvastatin Calcium" as MeSH terms, randomized controlled trials (RCTs) evaluating the efficacy and safety of rosuvastatin in AECOPD patients were retrieved from databases including PubMed, EMBASE, the Cochrane Library, Sinomed, CNKI, WanFang Data, and QIVIP. The search period extended through September 15, 2024. Two researchers independently screened the literature, extracted data, and assessed the risk of bias in the included studies. Meta-analysis was performed using RevMan 5.3 software, while sensitivity analyses and publication bias tests were conducted with Stata 17.0. Results: Eleven RCTs involving 911 patients were included, with a certain risk of bias. Rosuvastatin was found to improve forced vital capacity (FVC), forced expiratory volume in 1 second (FEV1), FEV1/FVC ratio, and peak expiratory flow (PEF). Additionally, it significantly reduced levels of hs-CRP, TNF-α, IL-6, IL-8, NE, and Gal-3. Conclusion: Despite the limited number of studies and potential bias, evidence suggests that rosuvastatin improves lung function and reduces inflammation in AECOPD, underscoring its potential value and emphasizing the need for further high-quality research.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.